Shots:
- Abbott has secured regulatory approval for its denosumab biosimilar in Thailand, increasing access to advanced treatments for osteoporosis and cancer-related bone loss
- Denosumab is a mAb that works by targeting RANKL, which regulates bone metabolism & osteoclast formation
- Abbott will offer denosumab as part of its strategy to expand access to quality medicines in oncology, immunology, and women’s health through partnerships with biotech companies
Ref: PRNewswire | Image: Abbott | Press Release
Related News:- Bio-Thera Secures the EC’s Approval for Usymro (Biosimilar, Stelara)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
